Dr. Tilley joined Innovimmune as Vice President of Discovery Chemistry in 2012. He joins us from Roche after four decades of a distinguished tenure as an industry leader in drug discovery and development. Most recently, Dr. Tilley was Senior Director, Discovery Chemistry, member of the Site Management Team and Chair of the Patent Advisory Committee at Roche. He has a proven track-record of successfully leading numerous discovery lead NME candidates into Clinical Development across multiple therapeutic areas, including PAF antagonists, integrin antagonists, glucokinase activators, nuclear hormone receptor modulators, 11b-HSD inhibitors, CRTH2 receptor antagonists and peptide neurohormone receptor modulators.

Dr. Tilley is an author of 100+ peer-reviewed journal articles, book chapters & abstract presentations; and inventor of 50+ worldwide patent applications. He obtained his Ph.D. in Chemistry at the California Institute of Technology. He is Past-Chair (2013) - North Jersey Section of the American Chemical Society, an Adjunct Professor of Chemistry at Fairleigh Dickinson University and Volunteer Instructor for the non-profit Students 2 Science (S2S) organization serving as an advocacy group promoting Science to inner city students in New Jersey. Dr. Tilley received the New Jersey American Chemical Society Lifetime Achievement Award in 2003 and was appointed as a Fellow of the American Chemical Society in 2011. Dr. Tilley has been awarded the 2014 and 2015 Faculty Member of the Year for Pharmacology & Drug Discovery by the Faculty of 1000 biomedical experts and received an Innovators Award from the New Jersey Inventors Hall of Fame in 2015.